跳至主要内容
临床试验/NCT05748392
NCT05748392撤回不适用

A Post-market, Multicenter, Prospective, Single-arm Study Evaluating Safety and Performance of the Veraflo™ Cleanse Choice Complete™ Dressing

Solventum US LLC1 个研究点 分布在 1 个国家开始时间: 2023年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
撤回
试验地点
1
主要终点
ADE/SADE

研究概览

简要总结

The purpose of this external clinical study is to demonstrate the safety and performance of the Veraflo™ Cleanse Choice Complete™ Dressing Kit which will be used in conjunction with the V.A.C.® Ulta™ Therapy Unit, utilizing V.A.C. Veraflo™ Therapy instillation functions.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Subject is at least 22 years old at time of consent.
  • •Subject OR Legal Authorized Representative is able to provide informed consent.
  • •Subject has been confirmed to have a chronic, acute, traumatic, sub-acute, or dehisced wound, partial-thickness burn, ulcer (such as diabetic, pressure or venous insufficiency), flap or graft.

排除标准

  • •Subject is pregnant prior to application of the initial dressing*
  • •*Women who have had surgical sterilization by a medically accepted method (i.e. tubal ligation, hysterectomy, or oophorectomy) or are post-menopausal, defined as not having menstruation for > 12 months will not be required to undergo pregnancy testing.
  • •Subject has been diagnosed with a malignancy in the wound.
  • •Subject has untreated osteomyelitis.
  • •Subject has an untreated systemic infection.
  • •Subject has active cellulitis in the peri-wound area.
  • •Subject has a known allergy or hypersensitivity to study materials: dressing(s), and/or dressing components such as acrylic or silicone adhesives or polyurethane.
  • •Subject has, in the opinion of the investigator, a clinically significant condition that would impair the Subject's ability to comply with the study procedures.
  • •Subject has had radiation directly to the wound area.
  • •Subject has been diagnosed with a major vascular deficit limiting arterial inflow to the wound region, as determined by the Investigator's interpretation of the Subject's medical history.
  • •Subject has necrotic tissue with eschar present. NOTE: After debridement of necrotic tissue and complete removal of eschar, Veraflo™ Therapy may be used.
  • •Subject is participating in another interventional clinical study or was enrolled in a clinical trial within the last 30 days of Visit
  • •Subject has non-enteric or unexplored fistula.
  • •Subject has a wound with any unexplored tunneling present.
  • •Subject has inadequate hemostasis at the wound site, as determined by the investigator.
  • •Subject has a wound with non-protected exposed vessels, anastomotic sites, organ, or nerves.

研究组 & 干预措施

Veraflo™ Cleanse Choice Complete™ Dressing Use with Assessments

Other

Subject will have Veraflo™ Cleanse Choice Complete™ dressing applied and used per instructions for use. 3D imaging and wound / peri-wound skin characteristics will be taken during the treatment.

干预措施: Wound and per-wound assessments While using Device (Device)

结局指标

主要结局

ADE/SADE

时间窗: Up to 14 days

Subject incidence of Adverse Device Events (ADEs) and Serious ADEs (SADEs) during the use of the device.

次要结局

  • Total Wound Volume (%)(Up to 14 days)
  • Total Wound Area (%)(Up to 14 days)
  • Non-viable Tissue (%)(Up to 14 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验